Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

SQZ Biotechnologies Company

Company price
0.024 USD 0.00(0%)
Last update at 2026-11-19T14:30:00Z
Market Cap
0.71M

Momentum Score

…

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.02
Low
0.02
High
52 Week Price Range
0.02
Low
0.03
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

SQZ Biotechnologies is a clinical-stage biotechnology company developing cell therapies using a proprietary microfluidic Cell Squeeze platform that transiently disrupts cell membranes to deliver therapeutic payloads for oncology and other indications. Long-term growth drivers include successful clinical proof-of-concept, expansion of platform applications, and partnerships or scalable manufacturing that may benefit commercialization prospects and support revenue generation.

The principal investment risks are clinical and regulatory failure, high cash burn with ongoing financing needs, and competition from established cell-therapy developers and alternative modalities.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.02
Dividend Yield
-
Revenue TTM
12.12M
Revenue Per Share
0.41
Gross Profit TTM
-39.67M
Debt / Equity
-
ROE
-203.37%
Net Debt
-59.57M
ROCE
-77.85%
Diluted EPS TTM
-2.43

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -71.64M -79.46M -68.74M -50.52M -32.20M
Net income -71.64M -79.46M -68.74M -50.52M -32.20M
Selling general administrative 21.10M 26.32M 25.72M 20.51M 18.27M
Reconciled depreciation 11.45M 11.68M 11.03M 10.94M 4.36M
Ebit - -75.83M -68.77M -51.06M -34.27M
Ebitda - -64.14M -57.74M -40.12M -27.85M
Operating income -60.77M -75.83M -68.77M -51.06M -34.27M
Interest expense - - - - 0.00M
Interest income 1.62M 1.22M 0.04M 0.55M 2.07M
Net interest income 1.62M 1.22M 0.04M 0.55M 2.07M
Total revenue 12.20M 21.03M 27.10M 21.00M 19.32M
Total operating expenses 72.96M 96.85M 95.87M 72.06M 53.58M
Total other income expense net -12.50M -4.86M -0.01M -0.01M -0.01M
Net income from continuing ops -71.64M -79.46M -68.74M -50.52M -32.20M
Net income applicable to common shares - -79.46M -68.74M -50.52M -32.20M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 99.90M 226.15M 231.14M 152.35M 115.55M
Other current assets - - - - 0.65M
Total liab 42.75M 102.18M 103.94M 225.87M 52.69M
Total stockholder equity 57.15M 123.98M 127.20M -73.52M 62.86M
Other current liab - 12.51M 26.66M 19.68M 3.74M
Common stock 0.03M 0.03M 0.03M 0.00M 0.00M
Capital stock 0.03M 0.03M 0.03M 0.00M -
Retained earnings -274.97M -195.51M -126.77M -76.25M -44.05M
Other liab - 9.20M 19.86M 22.59M -
Other assets 2.31M 2.63M 2.31M 2.32M 0.00M
Cash 63.71M 143.51M 170.36M 39.26M 59.57M
Total current liabilities 21.84M 33.22M 45.19M 38.28M 21.33M
Current deferred revenue - - - - 16.50M
Net debt - - - - -59.57M
Other stockholder equity - - - 0.03M 0.51M
Property plant equipment 29.39M 72.89M 52.01M 48.21M -
Total current assets 68.20M 150.63M 176.83M 101.82M 108.81M
Net tangible assets 57.15M 123.98M 127.20M -73.52M -
Short term investments - - 0.00M 59.03M 47.34M
Net receivables 0.00M 3.10M 2.44M 2.08M 1.25M
Accounts payable 2.51M 3.97M 3.71M 2.80M 1.09M
Accumulated other comprehensive income - - - - -0.00M
Non currrent assets other 2.31M 2.31M 2.31M 2.32M -0.00M
Non current assets total 31.70M 75.52M 54.31M 50.53M 6.73M
Capital lease obligations 27.47M 69.69M 47.09M 42.33M -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.04M -0.49M -0.61M 59.00M -10.68M
Change to liabilities - -22.41M -22.80M 4.85M -3.19M
Total cashflows from investing activities - -0.49M -0.61M 57.82M -12.85M
Total cash from financing activities 0.33M 4.23M 55.91M 116.42M 26.04M
Change to operating activities - -4.79M -9.03M -12.11M -2.64M
Net income -71.64M -79.46M -68.74M -50.52M -32.20M
Change in cash -74.05M -79.80M -26.84M 131.09M -20.30M
Begin period cash flow 86.54M 145.82M 172.66M 41.57M 61.88M
End period cash flow 12.50M 66.01M 145.82M 172.66M 41.57M
Total cash from operating activities -74.33M -83.55M -82.14M -43.15M -33.49M
Issuance of capital stock 0.30M 4.07M 56.40M 117.74M 25.95M
Depreciation 11.45M 11.68M 11.03M 10.94M 4.36M
Change to account receivables 0.00M 3.00M -1.11M -0.02M -1.01M
Sale purchase of stock - - - - 0.00M
Other cashflows from financing activities - - -1.90M -1.76M -1.76M
Change to netincome - 8.44M 8.51M 3.71M 1.19M
Capital expenditures 0.21M 0.52M 0.61M 1.18M 2.17M
Change in working capital -24.61M -24.20M -32.94M -7.28M -6.83M
Stock based compensation 4.60M 8.40M 8.51M 3.60M 2.11M
Other non cash items - - - 0.11M -
Free cash flow -74.55M -84.07M -82.75M -44.33M -35.66M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SQZB
SQZ Biotechnologies Company
-
-%
0.02 - - 0.06 0.44 0.99 -0.01
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

SQZ Biotechnologies Company

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

200 Arsenal Yards Boulevard, Watertown, MA, United States, 02472

617 758 8672

53

Name Title Year Born
Mr. Lawrence J. Knopf Esq. General Counsel & Secretary 1962
Dr. Marshelle Smith Warren M.D. Chief Medical Officer 1963
Dr. Robert S. Langer Jr., Ph.D., ScD Co-Founder & Member of Scientific Advisory Board 1949
Ms. Ipsita Roymoulik Ph.D. Senior Vice President of CMC & QUALITY NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…